Q-omics provides the consensus-scored NT5C3AP2 profile across patient tissues and cancer cell-line models. NT5C3AP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NT5C3AP2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, NT5C3AP2 RNA expression shows 17,121 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where NT5C3AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5C3AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5C3AP2 survival associations across molecular data types. NT5C3AP2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5C3AP2 RNA expression–survival associations across cancer types. High NT5C3AP2 expression shows unfavorable associations in KICH, but favorable associations in HNSC, SKCM, LUAD, BLCA and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NT5C3AP2 RNA expression.
This table summarizes NT5C3AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NT5C3AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5C3AP2 shows lower tumor expression in LUSC, THCA and COAD and higher tumor expression in KIRC, STAD and UCEC. The KIRC box plot shows higher NT5C3AP2 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with NT5C3AP2 in patient tissues and cancer cell lines. In patient samples, NT5C3AP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
